Business Wire

OSAKA-GAS

3.8.2022 04:02:06 CEST | Business Wire | Press release

Share
Global Deployment of Daigas Group’s Onsite Hydrogen Generation Technology with Hyundai Rotem Company

Daigas Gas and Power Solution Co., Ltd. (“DGPS”), a 100% subsidiary of Osaka Gas Co., Ltd. (TOKYO: 9532), has established an expanded business collaboration for onsite hydrogen generator technology with Hyundai Rotem Company (“HRC”), an affiliate of Hyundai Motor Group, allowing HRC to sell the generators outside South Korea.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220802005489/en/

Daigas Group (formerly Osaka Gas Group) launched the first model of “HYSERVE” (*1) , onsite hydrogen generator, in 2003 by adopting its accumulated knowledge on catalyst. DGPS introduced a new model “HYSERVE-300” with hourly hydrogen production capacity of 300 Nm3 in 2013. DGPS, as manufacturer of HYSERVE-300, has sold the units mainly to hydrogen fueling stations.

Then in 2019, DGPS granted HRC to manufacture and sell “Hy-Green”, hydrogen generator utilizing the technology of HYSERVE-300, enabling HRC to meet the increasing demand for hydrogen fueling stations in South Korea.

After confirming HRC’s successful launch of Hy-Green, DGPS has decided to globally deploy its HYSERVE technology through enabling HRC to sell Hy-Green outside of South Korea. DGPS believes this will contribute the prompt buildup of distributed hydrogen supply infrastructure which is necessary for the decarbonization in transportation sector.

Hy-Green will be sold by HRC for the on-site hydrogen fueling station for various hydrogen mobilities (small vehicles, buses, trucks, construction equipment, train, ships, drones and etc), fuel cell power plant, and biogas production facilities (to produce hydrogen) in order to expand the hydrogen supply chain.

HRC has already developed mass production capacity of Hy-Green and is ready for receiving inquiries from the world including those through Daigas Group.

Daigas Group including DGPS is going to expand its overseas energy business from upstream to downstream by fully utilizing its experiences in and out of Japan and its existing overseas business platforms.

(*1)

Onsite hydrogen generator developed and sold by Daigas Group. 36 units have been sold in Japan so far.

 

[Press Release on the launch of HYSERVE-300 (in Japanese)]

 

https://www.osakagas.co.jp/company/press/pr_2013/1206060_7831.html

[Corporate Profile]
 
Osaka Gas Co., Ltd.

Head Office:

4-1-2 Hiranocho, Chuo-ward, Osaka-city, Osaka

Representative:

Masataka Fujiwara (President & Representative Director)

Amount of Capital:

132,166,660,000 JPY

Date of Establishment:

April 10, 1897

Business Outline:

Natural gas distribution and supply; power generation and supply, etc.

 
Daigas Gas and Power Solution Co., Ltd.

Head Office:

3-5- 11 Doshomachi, Chuo-ward, Osaka-city, Osaka

Representative:

Nobushige Goto (President & Representative Director)

Amount of Capital:

100,000,000 JPY

Date of Establishment:

October 1, 2019

Business Outline:

Operation and maintenance of gas and power plants; power generation and supply; and engineering

 
Hyundai Rotem Company

Head Office:

37, Cheoldobangmulgwan-ro, Uiwang-si, Gyeonggi-do, 16082, Korea

Representative:

Yong-Bae, Lee (CEO)

Amount of Capital:

545,711,465,000 KRW

Date of Establishment:

July 1, 1977

Business Outline:

Total railway systems supply, Ground weapon systems supply, Steel, automobile production and hydrogen infrastructures supply, etc.

Contact Detail:

Duseop Lee / duseop.lee@hyundai-rotem.co.kr / +82-10-2648-5039

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye